Study of Treatment for HPV16+ ASC-US or LSIL

Exclusion Criteria

• •1. Patients with ASC-US/LSIL determined by cervical cytology at study entry that are HPV16 negative.
• •2. Histologic evidence of CIN2+
• •3. Patients with a diagnosis of immunosuppression or prolonged, active use of immunosuppressive medications such as steroids.
• •4. Prior vaccination with any HPV antigen (prophylactic or therapeutic).
• •5. Patients who are receiving any other investigational agents within 28 days prior to the first dose.
• •6. Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• •7. Patients with a history of autoimmune disease such as multiple sclerosis, exclusive of a history of thyroiditis, psoriasis, Sjrogen's, or inflammatory bowel disease.
• •8. Patients with a history of allergic reactions attributed to compounds used in agent preparation.
• •9. Patients who are pregnant or breast feeding.
• •10. Patient with active or chronic infection of HIV, HCV, or HBV.
• •11. Patients who have had a prior LEEP or cervical conization procedure.
• •12. History of prior malignancy permitted if patient has been disease free for ≥ 5 years; however individuals with completely resected basal cell or squamous cell carcinoma of the skin within this interval may be enrolled.
• •13. Inability to understand or unwillingness to sign an informed consent document.